Distribution of gastrointestinal neuroendocrine tumors in Europe: results from a retrospective cross-sectional study.
Epidemiology
Europe
Gastrointestinal
NEN
Neuroendocrine tumors
Outcome
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
21
12
2021
accepted:
31
03
2022
pubmed:
28
4
2022
medline:
22
3
2023
entrez:
27
4
2022
Statut:
ppublish
Résumé
Gastrointestinal (non-pancreatic) neuroendocrine tumors (GI-NETs) represent a rare but increasingly common tumor entity. Prognosis and biological behavior of these tumors is extremely heterogenous and largely dependent on the specific tumor site, stage and differentiation. However, systematic data on the epidemiology of GI-NET, especially in terms of geographic distributions are missing. We used the Oncology Dynamics database (IQVIA) to identify a total of 1354 patients with GI-NET from four European countries (Germany, France, Spain, UK) and compared them with regard to major patient and tumor related characteristics including patients' age, sex, tumor stage, tumor grading and differentiation. Out of the analyzed 1354 NET patients, 535 were found in the UK (39.5%), 289 in Germany (21.3%), 283 in Spain (20.9%) and 247 in France (18.2%). More patients were male than female (53.8% vs. 46.2%) with no significant differences between the analyzed countries. In contrast, the age distribution varied between the different countries, with the highest number of patients identified in the age groups of 61-70 years (31.0%) and 71-80 years (30.7%). The vast majority of patients showed a tumor origin in the small intestine, in German patients NET of the large intestine were slightly overrepresented and NET of the stomach underrepresented compared to all other countries. More than 80% of patients had stage IV disease at the time of diagnosis. Regarding tumor histology, most tumors showed a G2 tumor; interestingly, a G3 grading was found in 40.9% of patients in Germany (Ki-67 > 20%). The distribution of important patient- and tumor-specific characteristics of neuroendocrine tumors shows regional differences in four major European countries. These data may help to better understand the specific epidemiology of GI-NET in Europe.
Sections du résumé
BACKGROUND
BACKGROUND
Gastrointestinal (non-pancreatic) neuroendocrine tumors (GI-NETs) represent a rare but increasingly common tumor entity. Prognosis and biological behavior of these tumors is extremely heterogenous and largely dependent on the specific tumor site, stage and differentiation. However, systematic data on the epidemiology of GI-NET, especially in terms of geographic distributions are missing.
METHODS
METHODS
We used the Oncology Dynamics database (IQVIA) to identify a total of 1354 patients with GI-NET from four European countries (Germany, France, Spain, UK) and compared them with regard to major patient and tumor related characteristics including patients' age, sex, tumor stage, tumor grading and differentiation.
RESULTS
RESULTS
Out of the analyzed 1354 NET patients, 535 were found in the UK (39.5%), 289 in Germany (21.3%), 283 in Spain (20.9%) and 247 in France (18.2%). More patients were male than female (53.8% vs. 46.2%) with no significant differences between the analyzed countries. In contrast, the age distribution varied between the different countries, with the highest number of patients identified in the age groups of 61-70 years (31.0%) and 71-80 years (30.7%). The vast majority of patients showed a tumor origin in the small intestine, in German patients NET of the large intestine were slightly overrepresented and NET of the stomach underrepresented compared to all other countries. More than 80% of patients had stage IV disease at the time of diagnosis. Regarding tumor histology, most tumors showed a G2 tumor; interestingly, a G3 grading was found in 40.9% of patients in Germany (Ki-67 > 20%).
CONCLUSION
CONCLUSIONS
The distribution of important patient- and tumor-specific characteristics of neuroendocrine tumors shows regional differences in four major European countries. These data may help to better understand the specific epidemiology of GI-NET in Europe.
Identifiants
pubmed: 35476234
doi: 10.1007/s00432-022-04003-3
pii: 10.1007/s00432-022-04003-3
pmc: PMC10020282
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1411-1416Informations de copyright
© 2022. The Author(s).
Références
Front Horm Res. 2015;44:239-47
pubmed: 26303716
J Gastrointest Cancer. 2012 Sep;43(3):456-61
pubmed: 22125088
JCO Oncol Pract. 2020 Aug;16(8):e770-e778
pubmed: 32160136
Neuroendocrinology. 2004;80 Suppl 1:3-7
pubmed: 15477707
Eur J Cancer. 2012 Mar;48(5):662-71
pubmed: 21945100
Virchows Arch. 2022 Feb;480(2):359-368
pubmed: 34499237
Int J Mol Sci. 2019 Jun 22;20(12):
pubmed: 31234481
Nat Rev Endocrinol. 2020 Oct;16(10):590-607
pubmed: 32839579
Breast. 2017 Apr;32:247-255
pubmed: 28011074
Mol Imaging Biol. 2015 Jun;17(3):313-8
pubmed: 25319765
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Ann Oncol. 2020 Jul;31(7):844-860
pubmed: 32272208
Pathologica. 2021 Oct;113(5):377-387
pubmed: 34837096
Neuroendocrinology. 2021;111(3):217-236
pubmed: 32615560